Non-obvious profiles of patients who can additionally use famotidine Case report
Article Sidebar
Published:
Jun 30, 2025
Keywords:
famotidine, dyspepsia, urease test
Main Article Content
Abstract
Famotidine, a third-generation H2 blocker, inhibits hydrochloric acid secretion by competitively blocking histamine H2 receptors in the gastric parietal cell wall. It is primarily used to treat symptomatic gastroesophageal reflux disease, but its use is not always considered in dyspepsia, prior to a planned gastroscopy with a urease test, and in patients with medical conditions and polypharmacy.
Article Details
How to Cite
Mokrowiecka, A. (2025). Non-obvious profiles of patients who can additionally use famotidine. Medycyna Faktow (J EBM), 18(2(67), 313-316. https://doi.org/10.24292/01.MF.0225.21
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Świdnicka-Siergiejko A, Marek T, Waśko-Czopnik D et al. Postępowanie diagnostyczno-terapeutyczne w chorobie refluksowej przełyku. Konsensus Polskiego Towarzystwa Gastroenterologii 2022. Med Prakt. 2022; 6: 38-74.
2. Dąbrowski A. Nowości w dziedzinie hamowania wydzielania kwasu solnego w żołądku. Gastroenterologia Kliniczna. 2014; 6(4): 127-33.
3. Ford AC, Moayyedi P, Black CJ et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021; 53(1): 8-21.
4. Dąbrowski A, Marlicz K. Dyspepsja. In: Interna Szczeklika. Medycyna Praktyczna. Kraków 2023.
5. Moayyedi PM, Lacy BE, Andrews CN et al. ACG and CAG Clinical Guideline: management of dyspepsia. Am J Gastroenterol. 2017; 112: 988-1013.
6. Black CJ, Paine PA, Agrawal A et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022; 71(9): 1697-723.
7. Adrych K, Solnica B, Rożynek E et al. Interna Szczeklika 2024/25. Mały podręcznik. Praca zbiorowa. Medycyna Praktyczna, Kraków 2024.
8. Huang YH, Cai WK, Yin SJ et al. Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study. Eur J Prev Cardiol. 2022; 29(14): 1854-65.
9. Kim J, Ogai A, Nakatani S et al. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol. 2006; 48: 1378-84.
10. Wang D, Chen H, Luo Y. Histamine H2 Receptor Antagonists in the Treatment and Prevention of Heart Failure. Int J Gen Med. 2024: 17: 6047-52.
11. Khawaja M, Thakker J, Kherallah R et al. Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. Cardiovasc Drugs Ther. 2024; 38(1): 181-9.
2. Dąbrowski A. Nowości w dziedzinie hamowania wydzielania kwasu solnego w żołądku. Gastroenterologia Kliniczna. 2014; 6(4): 127-33.
3. Ford AC, Moayyedi P, Black CJ et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021; 53(1): 8-21.
4. Dąbrowski A, Marlicz K. Dyspepsja. In: Interna Szczeklika. Medycyna Praktyczna. Kraków 2023.
5. Moayyedi PM, Lacy BE, Andrews CN et al. ACG and CAG Clinical Guideline: management of dyspepsia. Am J Gastroenterol. 2017; 112: 988-1013.
6. Black CJ, Paine PA, Agrawal A et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022; 71(9): 1697-723.
7. Adrych K, Solnica B, Rożynek E et al. Interna Szczeklika 2024/25. Mały podręcznik. Praca zbiorowa. Medycyna Praktyczna, Kraków 2024.
8. Huang YH, Cai WK, Yin SJ et al. Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study. Eur J Prev Cardiol. 2022; 29(14): 1854-65.
9. Kim J, Ogai A, Nakatani S et al. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol. 2006; 48: 1378-84.
10. Wang D, Chen H, Luo Y. Histamine H2 Receptor Antagonists in the Treatment and Prevention of Heart Failure. Int J Gen Med. 2024: 17: 6047-52.
11. Khawaja M, Thakker J, Kherallah R et al. Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. Cardiovasc Drugs Ther. 2024; 38(1): 181-9.